TABLE III.

The percentage target dose degradation %ΔD_98,95 for CTV _prostate (P) and CTV _SV (S) for zero-PTV-margin plan, and the optimized PTV margins obtained by CP_OM technique across 19 patients.

ID	Zero-PTV-plan %ΔD98,95(%)	CPOM PTV(mm)
1	P: 4.9 S: 14.5	P: 2 S: 8
2	P: 5.8 S: 6.4	P: 10 S: 5
3	P: 5.3 S: 1.3	P: 5 S: 3
4	P: 7.7 S: 14.4	P: 5 S: 3
5	P: 1.3 S: 8.5	P: 2 S: 6
6	P: 0.8 S: 8.5	P: 1 S: 3
7	P: 2.2 S: 0.0	P: 2 S: 0
8	P: 1.7 S: 0.0	P: 4 S: 3
9	P: 2.9 S: 16.9	P: 6 S: 18
10	P: 11.1 S: 24.7	P: 7 S: 15
11	P: 9.5 S: 0.0	P: 9 S: 0
12	P: 7.5 S: 9.8	P: 9 S: 5
13	P: 2.7 S: 31.4	P: 5 S: 4
14	P: 0.8 S: 32.9	P: 4 S: 8
15	P: 0.8 S: 0.0	P: 1 S: 0
16	P: 2.4 S: 0.0	P: 2 S: 2
17	P: 3.1 S: 24.8	P: 3 S: 5
18	P: 2.6 S: 4.6	P: 4 S: 4
19	P: 0.7 S: 0.0	P: 2 S: 0